久久国产精品无码一区二区三区 ,久久婷婷色综合老司机

Talimogene Laherparepvec

NMR下載 COA and HPLC MSDS下載
names：
Talimogene laherparepvec
CAS號：
1187560-31-1
MDL Number：
MF(分子式)： MW(分子量)：
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規(guī)格	純度	價格 (￥)	現(xiàn)價(￥)	特價(￥)	庫存描述	數(shù)量	總計 (￥)
DBK502137-500mg	500mg		￥ 0.00	￥ 0.00		Get quote	- +	￥ 0.00
DBK502137-100mg	100mg		￥ 0.00	￥ 0.00		Get quote	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產(chǎn)品

*產(chǎn)品名稱：

CAS號：

產(chǎn)品編號：

需求描述：

請準(zhǔn)確填寫您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗證碼：

詢價

中文別名	Talimogene Laherparepvec
英文別名	Talimogene laherparepvec
CAS號	1187560-31-1
Inchi
InchiKey
分子式 Formula
分子量 Molecular Weight
溶解度Solubility
性狀	NA
儲藏條件 Storage conditions

Talimogene Laherparepvec使用注意事項：
1.實驗前需戴好防護(hù)眼鏡，穿戴防護(hù)服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時實驗操作需要手套箱內(nèi)完成以免對實驗人員造成傷害。
3.取樣品的移液槍頭需及時更換，必要時為避免交叉污染盡可能選擇濾芯吸頭。
4.稱量藥品時選用稱量紙，并無風(fēng)處取藥和稱量以免揚撒，試劑的容器使用前務(wù)必確保干凈，并消毒。
5.取藥品時盡量采用多個藥勺分別使用，使用后清洗干凈。
6.實驗后產(chǎn)生的廢棄物需分類存儲，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染。
大規(guī)格定制：定制產(chǎn)品請將信息發(fā)送至sales@bio-fount.com。
Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

產(chǎn)品說明	Organic Acids
Introduction
Application1	Talimogene laherparepvec is an oncolytic immunotherapy that is derived from Herpes Simplex Virus type-1 (HSV-1)3. It has been modified to replicate within tumor cells and to produce the immune response stimulatory protein, human GM-CSF (granulocyte macrophage colony stimulating factor)3. The medication causes the death of tumor cells and the release of tumor-derived antigens3. It is believed that together with GM-CSF, talimogene laherparepvec can promote a systemic anti-tumor immune response and an effector T-cell response3. Mice subjects involved in talimogene laherparepvec treatment studies that had complete regression of their primary tumors following therapy were resistant to subsequent tumor rechallenge3.The genetic modifications to talimogene laherparepvec from HSV-1 include deletion of the ICP34.5 and ICP47 genes3. Whereas anti-viral immune responses defend normal cells following infection by talimogene laherparepvec, tumors have been shown to be susceptible to injury and cell death from ICP34.5-deficient HSV-1 derived viruses, including talimogene laherparepvec3. Moreover, deletion of ICP47 prevents the down-regulation of antigen presentation molecules in the targeted tumor cells and increases the expression of the HSV US11 gene, thereby enhancing the talimogene laherparepvec viral replication in tumor cells and increases chances of tumor cell injury and death3.Although the talimogene laherparepvec virus is specifically modified to infect and multiply inside melanoma cells and uses melanoma cells' own machinery to multiply, the medication is not designed to multiply inside healthy cells, which it is also capable of entering4.TargetActionsOrganismAHeparan sulfateNot AvailableHumansADNA polymerase catalytic subunitactivatorHHV-1ADNA polymerase catalytic subunitactivatorHHV-3
Application2
Application3